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Abstract
Period 2-mutant mice (Per2m/m), which possess a circadian dysfunction, recapitulate the
retinal vascular phenotype similar to diabetic retinopathy (DR). The vascular dysfunction in
Per2m/m is associated with an increase in connective tissue growth factor (CTGF/CCN2).
At the molecular level, CTGF gene expression is dependent on the canonical Wnt/β-catenin
pathway. The nuclear binding of β-catenin to a transcription factor, lymphoid enhancer
binding protein (Lef)/ T-cell factor (TCF/LEF), leads to downstream activation of CTGF. For
this study, we hypothesized that the silencing of Per2 results in nuclear translocation and
subsequent transactivation of the CTGF gene. To test this hypothesis, we performed immu-
nofluorescence labeling for CTGF in retinal sections from wild-type (WT) and Per2m/m
mice. Human retinal endothelial cells (HRECs) were transfected with siRNA for Per2, and
the protein expression of CTGF and β-catenin was evaluated. The TCF/LEF luciferase
reporter (TOPflash) assay was performed to validate the involvement of β-catenin in the
activation of CTGF. Per2m/m retinas exhibited an increased CTGF immunostaining in gan-
glion cell layer and retinal endothelium. Silencing of Per2 using siRNA resulted in an
upregulation of CTGF and β-catenin. The TOPflash assay revealed an increase in lumines-
cence for HRECs transfected with Per2 siRNA. Our studies show that loss of Per2 results
in an activation of CTGF via nuclear entry of β-catenin. Our study provides novel insight
into the understanding of microvascular dysfunction in Per2m/m mice.
PLOS ONE | DOI:10.1371/journal.pone.0163367 September 23, 2016 1 / 13
a11111
OPENACCESS
Citation: Jadhav V, Luo Q, M. Dominguez J, 2nd,
Al-Sabah J, Chaqour B, Grant MB, et al. (2016)
Per2-Mediated Vascular Dysfunction Is Caused by
the Upregulation of the Connective Tissue Growth
Factor (CTGF). PLoS ONE 11(9): e0163367.
doi:10.1371/journal.pone.0163367
Editor: Gianluca Tosini, Morehouse School of
Medicine, UNITED STATES
Received: July 28, 2016
Accepted: September 7, 2016
Published: September 23, 2016
Copyright: © 2016 Jadhav et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: This work was supported by Ralph and
Grace Showalter Trust Fund, International Retinal
Research Foundation (http://www.irrfonline.org/)
and an unrestricted award from Research to
Prevent Blindness (RPB; https://www.rpbusa.org/
rpb/?) foundation to Department of
Ophthalmology, Indiana University to AB;
EY022091-01 (https://nei.nih.gov/) to BC; and
R01EY007739, R01EY012601, and R0110170
(https://nei.nih.gov/) to MBG. The funders had no
Introduction
Circadian rhythms play an important role in regulatingmany biochemical, physiological, and
behavioral processes such as carbohydrate metabolism, sleep-wake cycle, and feeding. Dis-
turbed circadian rhythms or circadian dyssynchrony is observed in shift work disorders and
include, jet-lag, advanced sleep phase syndrome, and irregular sleep-wake rhythm [1]. Diabetic
retinopathy (DR) is a long-term complication of diabetes. During the first twenty years of dia-
betes, nearly all patients with Type 1 diabetes (T1D) and>60% of patients with Type 2 diabetes
(T2D) will develop some form of the DR [2]. We previously identifiedDR as a disease of circa-
dian dysfunction and demonstrated dampened expression of clock regulatory genes in the ret-
ina during T2D [3].
The core oscillator that drives the clock, the suprachiasmatic nucleus (SCN), is located in
the hypothalamus; At the molecular level, circadian rhythms are orchestrated by interlocking
autoregulatory transcription/translation feedback loops involving a set of clock genes [4].
Compelling evidence suggests that the retina is under the influence of circadian rhythms [5].
Notably, the retinal clock is independent of the SCN and can influence the rhythms generated
by the SCN [6]. The clock gene rhythm in the retina is generated in a cell-autonomous manner.
In the retina, melatonin release [7], dopamine synthesis [8], gamma-amino butyric acid
(GABA) turnover [9] and rhodopsin gene expression [10] exhibit a physiological circadian
rhythm. The retinal clock also regulates cell survival and growth processes in the eye such as
photoreceptor survival in animal models of retinal degeneration [11], ganglion cell viability
during aging [12] and important retinal functions such as phagocytosis, disk shedding, and
corneal thickness. In mouse retina, several inner retinal cell types such as horizontal cells, bipo-
lar cells, dopaminergic amacrine cells and ganglion cells express most of the clock regulatory
genes [13].
In a previous study, we demonstrated the critical role of clock regulatory gene Per2 and
found that Per2m/mmice recapitulate a vascular phenotype of DR [14]. The prominent role of
the clock gene Per2 is observed in a variety of human and mouse studies. In humans, a muta-
tion in Per2 leads to a condition referred to as advanced sleep phase syndrome (ASPS), which
is characterized by a short sleep cycle [15, 16]. Per2m/mmice possess a range of pathological dis-
orders, such as cancer [17], shortened life-span, auto-amputations, increased alcohol consump-
tion [18], and endothelial dysfunction [19, 20]. Therefore, understanding the mechanism of
Per2 dysregulation and the above disorders, specifically at the retina, is of intense interest to
develop pharmacological targets.
CTGF is a secreted protein known to be involved in a variety of cellular events, such as
angiogenesis, skeletogenesis, and wound healing [21]. In the retina, CTGF is known to be upre-
gulated in diabetes, and its inhibition protects from the development of DR [22]. CTGF is an
important downstream effector of transforming growth factor β1 (TGF-β1), a known inducer
of extracellularmatrix components, such as collagen and fibronectin [23]. Our previous studies
on Per2m/m retinas showed an increase in TGF-β1, CTGF, and fibronectin, suggesting an active
involvement of the TGF-β1-CTGF pathway in vascular dysfunction of Per2m/m mice [14]. The
Wnt-β-catenin signaling pathway plays an important role in an upregulation of CTGF in the
retina [22]. The nuclear binding of non-phosphorylated β-catenin to lymphoid enhancer bind-
ing protein (Lef)/T-cell factor (TCF) TCF/LEF was demonstrated as a major regulator of
CTGF activation [24].
While our previous studies on Per2m/m retinas showed an increase in CTGF, the exact
mechanism behind the upregulation of CTGF in Per2m/m retinas remains unknown. The pur-
pose of this mechanistic study was to determine whether silencing of Per2 results in activation
of the β-catenin-CTGF pathway and associated phenotypes. First, we performed scotopic
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electroretinogram (ERG) measurements and measured retinal thickness using the optical
coherence tomography (OCT) in the retina of Per2m/mmice. Next, we measured CTGF expres-
sion in the retina from Per2m/mmice, and we assessed the effect(s) of Per2-silencing in HRECs
on β-catenin and CTGF. Ultimately, our study highlights that the DR-like vascular phenotype
observed in Per2m/m mice is due to a β-catenin mediated increase in CTGF expression.
Materials and Methods
Animal Studies
All animal studies were performed in accordance with The Guiding Principles in the Care and
Use of Animals (NIH) and the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. The protocol was approved by the institutional animal care and use commit-
tee of the University of Florida. The animal studies were completed while the authors were at
the University of Florida, since then the research team has moved to the Indiana University
School of Medicine.Wild type and Per2m/m female mice (B6.129-Per2tm1Drw/J) at 12 months of
age were obtained as a gift from Dr. Choogon Lee, Florida State University, Tallahassee, FL).
All animal studies were performed between 11 AM and 1 PM.
For the ERG studies, the animals were dark-adapted overnight. The mice were anesthetized
with a mixture of Ketamine and Xylazine. The pupils were dilated using 1% tropicamide and
2.5% phenylephrine. The platinum loop electrode (Grass Telefactor, Rhode Island, USA) was
placed over the cornea after the application of Gonak (Hypromellose 2.5% solution Akorn Inc,
Lake Forest, IL), and the scotopic ERG recordings were performed using an LKC NGIT-100
recording machine (LKC Technologies, Inc, Gaithersburg,MD, USA).
The OCT assessments were performed on anesthetizedmice using a Bioptigen Spectral
Domain Ophthalmic Imaging System (LeicaMicrosystems Inc, Buffalo Grove, IL). Total reti-
nal thickness was evaluated by manually placing of calipers extending from the retinal nerve
fiber layer (RNFL) up to the retinal pigment epithelium (RPE), as describedpreviously [25].
The brightly luminous portion of the choroid under the RPE was omitted during the analysis.
Culture of HRECs
HRECs were purchased from ATCC (Manassas, VA). Cells from passage two to seven were
used for all experiments. Cells were cultured in pre-coated flasks/dishes/coverslipswith attach-
ment factor (AF), and M131 media was supplemented with microvascular growth factor
(MVGS) (M131 Kit, Life Technologies, Grand Island NY) with 100U of antibiotic-antimycotic
(Gibco-Life Technologies).
Staining retinal sections for CTGF
The retinal vessels were labeled with an intravenous injection of Rhodamine-conjugatedBan-
deiraea simplicifolia (BS)-1 isolectin (0.1 mg/kg; Vector Laboratories) 30 minutes prior to
euthanasia. The eyeballs frommice were enucleated, fixed in 4% paraformaldehyde and
embedded in paraffin. Sectionswere then deparaffinized and incubated in citrate plus buffer
(ScyTek laboratories, West Logan, UT) for epitope retrieval [26]. The retinal sections were
then incubated with anti-CTGF primary antibodies (1:100; Abcam, Cambridge,MA) overnight
at +4°C. On the following day, after careful washing of unbound primary antibodies, the retinal
sections were incubated with Alexa Fluor 488 secondary antibodies (1:800; Molecular Probes-
Life Technologies). Two hours after incubation with secondary antibodies, the retinal sections
were washed in PBS and mounted in a SlowFade gold with DAPI mounting media and imaged
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using a confocal microscope (Zeiss LSM 510 META; Carl ZeissMicroImaging GmbH, Jena,
Germany).
siRNA transfections for Per2
HRECs were grown and transfected with 10μM Per2 siRNA (#s30208; Ambion-Life Technolo-
gies) using LipofectamineRNAiMax reagent (Life Technologies) and were harvested after 24h
for RNA analysis and protein analysis by Western blot. Cells transfected with negative control
siRNA (#4390846, Ambion-Life Technologies) were used as a control. siRNA-transfected cells
were harvested between 11 AM and 1 PM and processed for protein or mRNA expression.
qRT-PCR for mRNA analysis
RNA was isolated using TRIzol (Life Technologies) as per the manufacturer’s protocol. One
microgram of RNA was reverse transcribedusing iScript cDNA synthesis kit (Bio-Rad, Hercu-
les, CA). Gene-specificprimers were used along with TaqMan Fast Universal master mix (Life
Technologies), and respectivemRNA levels were assessed using quantitative PCR (ViiA 7,
Applied Biosystems). All genes were normalized to β-actin. Primers used were: Per2 (Hs
00256144), CTGF (Hs 00170014), β-catenin (CTNNB1Hs 00355049), and β-actin (Hs
01060665) from Applied Biosystems.
Western blotting
The Per2 siRNA-transfected cells were pelleted and lysed after 24 hrs in a RIPA buffer (R0278,
Sigma-Aldrich, St. Louis, MO). Nuclear and cytoplasmic extracts were prepared using an
NE-PER Nuclear and Cytoplasmic extraction kit (Thermo Fisher Scientific,Grand Island, NY)
Protein concentration was estimated using the BCA assay (Pierce, Thermo Scientific, Rockford,
IL), and equal amounts of proteins (50 μg) were loaded and separated on 4–12% Bis-Tris gels
(Novex, Life technologies, Carlsbad, CA). Proteins were transferred to a PVDFmembrane
(Life Technologies), which was blocked with 5% milk or BSA as per the antibody requirement.
The following antibodies were used for probing: CTGF (1:1000; Abcam), and β-catenin
(1:1000; Cell Signaling Technology, Boston,MA). The PVDFmembranes were incubated with
the aforementioned primary antibodies overnight at +4°C. The following set of antibodies were
used as a secondary loading control: α-tubulin (1:800) and Histone-H3 (1:2000; Sigma-Aldrich,
St. Louis, MO). The secondary antibody incubations were performed for two hours at room
temperature. The bands were visualized using ECL2 western blotting substrate (Pierce) on a
XRS gel documentation system with Quantity One software (Bio-Rad, CA).
TCF/LEF Luciferase assay
HRECs were co-transfectedwith a TCF/LEF construct (Cignal reporter assay kit, Qiagen Sci-
ences, MA,) and a 10 μM Per2 or a control siRNA as per the manufacturer’s protocol. The cells
were also co-transfectedwith a target gene luciferase reporter constructs and constitutively
expressing Renilla construct. After 24h of transfection, the cells were harvested, and lysates
were prepared and measured for luminescence using a Dual Luciferase Assay system (Promega,
Madison,WI) on a Synergy H1 Hybrid Reader (BioTek, Winooski, VT). The ratio of lumines-
cence for luciferase to Renilla was plotted for all experimental conditions.
Statistics
The data were expressed as mean ± SEM. Statistical analysis was performed using a Graph
Pad-Prizm 6 (GraphPad Software La Jolla, CA) software. The statistical significancewas
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evaluated using Student’s t-test or a Two-Way ANOVA followed by a Bonferroni’s post- hoc
test. The data were considered to be statistically significant when the p-value was less than 0.05.
Results
Per2m/m mice show decreases in ERG amplitude and retinal thickness
In order to determine the extent of neuronal dysfunction and the neurodegenerative changes
in the retina of Per2m/mmice, we performed scotopic ERGmeasurements and measured retinal
thickness using the OCT. We found that the amplitude of ERG wave was reduced overall in the
Per2m/m retinas (Fig 1A), as both the ‘a’ wave and the ‘b’ wave were decreased in the Per2m/m
animals. While the difference in ERG amplitude was statistically significant for the ‘b’ wave, we
observed that this difference remained insignificant for the ‘a’ wave (Fig 1B). In addition, we
Fig 1. Per2m/m mice exhibit decreased ERG amplitude. (A) Representative ERG trace for 15 db stimuli
showing a decrease in ERG amplitude in Per2m/m retinas (B) Line graph showing a similar decrease in ERG
response for both ’a’ and ’b’ wave in Per2m/m mice for a series of stimuli in the range of 45–15 db. n = 7,
*p<0.05.
doi:10.1371/journal.pone.0163367.g001
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observed a profound decrease in retinal thickness in Per2m/mmice, suggestive of neurodegener-
ative changes (Fig 2).
Retinas from Per2m/m mice exhibit increases in CTGF expression in
retinal blood vessels
To test whether neuronal changes of the Per2m/mmice alters CTGF expression in retinal blood
vessels, we stained the retinal sections with CTGF antibodies. Prior to euthanasia, the retinal
vessels were stained for BS-1 isolectinwith a tail vein injection of rhodamine-conjugated isolec-
tin. The overall retinal neuropile exhibited an increase in CTGF expression (Fig 3A), which
was more profound in the ganglion cell layer (GCL; Fig 3B) and the outer plexiform layer
(OPL; Fig 3C). The retinal vessel wall exhibited intense staining of CTGF in Per2m/m mice as
compared to theWT animals (Fig 3D).
siRNA Per2 upregulates β-catenin and CTGF expression in the retina of
the Per2m/m mice
We used cultured human retinal endothelial cells (HRECs). The HRECs were transfectedwith
either siRNA Per2 or a scrambled control. The mRNA expression of Per2, β-catenin and CTGF
was evaluated using qRT-PCR. As shown in Fig 4A, the Per2 siRNA treatment resulted in a
2-fold decrease in Per2 expression. Conversely, siRNA Per2-transfectedHRECs showed a
1.6-fold increase in β-catenin (p<0.05; Fig 4B) and a 2.5-fold increase in CTGF (p<0.05; Fig 4C)
Fig 2. Per2m/m mice show a decrease in retinal thickness. (A) The OCT scans of the whole retina showing representative images from the WT
and Per2m/m mice. RNFL, retinal nerve fiber layer; GCL/IPL, Ganglion cell layer/inner plexiform layer; INL, Inner nuclear layer; OPL, Outer
plexiform layer; ONL, Outer nuclear layer; ELM/IS/OS, external limiting membrane/inner segment of photoreceptors/outer segment of
photoreceptors; RPE, Retinal pigment epithelial layer. (B) The measurements of retinal thickness were performed by placing the 2 calipers (C01 &
C02) near the optic nerve; the bar chart shows a decrease in retinal thickness of Per2m/m. n = 6, *p<0.05.
doi:10.1371/journal.pone.0163367.g002
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mRNA levels. To evaluate whether changes in mRNA expression also translated to an increase
in β-catenin and CTGF, we performed a western blot of HRECs transfected with siRNA Per2.
We observeda similar increase in the protein expression of CTGF and β-catenin as a result of
Per2 silencing (Fig 4D).
Fig 3. The increase in CTGF staining in Per2m/m retinas. (A) Retinal sections were stained with CTGF antibodies. The photomicrographs show an
increase in staining for CTGF (green) in the GCL (white arrows) and OPL (white arrows) in Per2m/m mice; the bar-graph shows quantification of mean
fluorescence intensity for (B) GCL and (C) OPL. (D) Retinal endothelial cells were stained with BS-isolectin (red) prior to euthanasia. The staining
reveals an increase in CTGF expression in vessels co-stained with BS-1 isolectin. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, Inner nuclear
layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PR, photoreceptors. n = 3.
doi:10.1371/journal.pone.0163367.g003
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Per2 silencing causes dislodgment and nuclear transport of β-catenin
To determine whether Per2-silencing would result in a dislodgement of β-catenin from the
cytoplasm and its subsequent transfer to the nucleus, we transfected the HRECs with siRNA
Per2 and stained with CTGF antibodies. The nuclear and cytoplasmic fractions of Per2 and
control siRNA treated HRECs were separated. TheWestern blots were performed to determine
the protein expression of β-catenin. The Histone H3 and α-tubulin were used as loading con-
trols for nuclear and cytoplasmic fractions respectively. As shown in Fig 5, Per2 siRNA-treated
HRECs showed an increase in β-catenin staining in a nuclear fraction as compared to the cyto-
plasmic fraction, suggesting nuclear entry of β-catenin due to Per2-silencing.
Fig 4. Per2-silencing in HRECs results in an increase in β-catenin and CTGF. HRECs were treated with either scrambled control siRNA or Per2
siRNA; bar graphs show mRNA expression of (A) Per2, (B) β-catenin and (C) CTGF, n = 4. (D) Western blots show a similar change in the protein
expression of β-catenin and CTGF following a treatment with siRNA Per2. n = 3, * p<0.05.
doi:10.1371/journal.pone.0163367.g004
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Per2-silencing results in nuclear binding of β-catenin resulting in
activation of CTGF
We used TOPflash assay to determine whether Per2 silencing results in a nuclear binding of
TCF/LEF and downstream activation of CTGF. We co-transfected the HRECs with the siRNA
Per2 and the TOPflash plasmid. We observed a 4-fold increase (p<0.05) in luciferase activity
following Per2 silencing that was consistent with nuclear binding of TCF/LEF. (Fig 6).
Discussion
Per2m/mmice exhibit the pathologic hallmark features consistent with DR [14]. This study
identified a novel mechanism of retinopathy development by defining a critical role of β-cate-
nin-mediated CTGF increase in Per2m/mmice. The Per2m/mmice exhibit phenotypic defects
such as a decrease in ERG amplitude and a profound decrease in retinal thickness with concur-
rent increase in CTGF expression. The in vitro studies using siRNA Per2 reveal that β-catenin
binding to TCF/LEF factors play an integral role in CTGF upregulation. Additionally, we
found that the amplitude of ERG wave was reduced overall in the Per2m/m retinas, suggestive of
neurodegenerative changes.
TGF-β1 [27] and CTGF [28] localization in the ganglion cell layer of the retina are linked to
a decrease in ERG amplitude in pathological states such as diabetes [29]. Our immunofluores-
cence studies provide supporting evidence of a similar increase in CTGF in ganglion cell layer
of retinal sections of Per2m/mmice. Therefore, we believe that a decrease in ERG amplitude in
Per2m/mmice is attributed, at least in part, to an activation of CTGF in retinal ganglion cells.
Fig 5. Nuclear entry of β-catenin after treatment of HRECs with siRNA Per2. Per2 or control siRNA-treated HRECs were
processed to separate nuclear and cytoplasmic fractions. Representative western blots showed nuclear translocation of β-
catenin after treatment with Per2 siRNA. Histone H3 and α-tubulin were used as loading controls for nuclear and cytoplasmic
fractions, respectively n = 3.
doi:10.1371/journal.pone.0163367.g005
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Other retinal cell types, such as bipolar cells and Müller cells, are also known to contribute to
the ERG ‘b’ wave. Thus, we speculate that there may be a similar increase in CTGF expression
in these cell types; however, this requires further validation by individual cell staining. The
decrease in the OCTmeasurements of Per2m/m retinas provides further insights for undertak-
ing mechanistic studies of the other cell types of retinal neuropile.
Our ERG and OCT findings differ from previous studies by Ait-Hymed et al. [30], which
reported no difference in ERG amplitude and OCT recordings betweenWT and Per1/Per2
knockout animals. This discrepancy is potentially due to differences between the two different
genetic strains. For instance, the genetic strain of Per2m/mmice (Per2tm1Drw) used in our studies
does not produce detectable protein levels of PER2 [31]. However, the strain used in studies by
Ait-Hymed et al. (Per2tm1Brd) has the potential to generate a protein with a deletion of 87
amino acids [32]. Thus, we believe that inconsistencies in ERG and OCT findingsmay be
attributed to translated PER2 protein.
The predominant finding of our study is defining the critical role of CTGF in the develop-
ment of retinopathy in Per2m/mmice. The Per2m/m retinas exhibited an increased CTGF immu-
nostaining in ganglion cell layer and retinal endothelium.We observed an upregulation of
CTGF and β-catenin associated with Per2 silencing. CTGF is known to play a critical role in
the pathogenesis of DR by promoting extracellularmatrix (ECM) protein production [24 25].
In this study, the animals lacking the functional CTGF allele (CTGF+/−) and made diabetic
using streptozotocin (STZ) did not develop classical symptoms of DR, such as an increase in
Fig 6. β-catenin binds to TCF/LEF factors after treatment with siRNA Per2. The TOPflash assay was performed to study the
nuclear binding of β-catenin after treatment with siRNA Per2. The bar chart showing a significant increase in luciferase signal
following a treatment with siRNA Per2 when compared to a control siRNA. n = 3, * p<0.05.
doi:10.1371/journal.pone.0163367.g006
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ECM thickening, pericyte dropout and an increase in acellular capillaries. In contrast, the ani-
mals that possessed the (CTGF+/+) functional allele developed a full spectrumof the above fea-
tures of DR. Taken together, this suggests that CTGF is involved in the pathological change of
the retina in diabetes. Our study further ascertained an important role of CTGF in retinal vas-
cular dysfunction due to lack of Per2.
Our studies show that clock function (i.e., Per2), β-catenin and CTGF are mechanistically
interlinked, and this trio together might represent an important determinant in the pathogene-
sis of DR. For instance, previous studies suggest that hyperactivity of β-catenin is linked to
pathological retinal neovascularization [33] and hereditary vascular disorders [34, 35]; and
inhibition of Wnt pathway has been shown to be protective in DR due to downregulation of
the CTGF [22]. Our study demonstrated that Per2 is an important upstream regulator of the β-
catenin-CTGF pathway in DR, and maintaining optimum levels of Per2 are necessary for pro-
tection from DR.
We previously reported a loss of junctional integrity of VE-Cadherin in Per2m/mmice [14].
β-catenin is a critical junctional protein. The previous study suggests an important role of
CTGF in proliferative DR [36]. However, the involvement of CTGF in retinal permeability is
not well-defined.We believe that β-catenin is critical in mediating an increase in CTGF expres-
sion in Per2m/mmice. Our studies using a TOPflash assay reveal that the silencing of Per2
results in a translocation of β-catenin from the cytoplasm to the nucleus and subsequent down-
stream activation of CTGF. These findings indicate a β-catenin-mediated increase in CTGF
expression is responsible for the DR-like vascular phenotype observed in Per2m/mmice. More-
over, the β-catenin expression is increased following Per2-silencing in HRECs, in agreement
with previous studies performed on colon carcinoma cells [17]. Our study demonstrated a sim-
ilar increase in β-catenin in both healthy cells and the retina.
Another possible mechanism of nuclear translocation of β-catenin may be the result of the
common phosphorylation and degradative pathway shared by both PER2 protein and β-cate-
nin. The casein kinase 1 (CK1) acts as a key mediator that regulates nuclear import of β-catenin
by virtue of its dual control over the phosphorylation of the PER2 and β-catenin.We speculate
that in the Per2m/mmice, CK1 shifts its enzymatic activity towards PER2, leading to its
enhanced degradation and, therefore, reduced β-catenin phosphorylation. This, in turn, results
in the nuclear entry of β-catenin, leading to downstream activation of targets such as CTGF.
In conclusion, our study identified a novel pathway of retinopathy progression in Per2m/m
mice by ascertaining the critical role of β-catenin-mediated CTGF increase. Further, our study
paves a way for the development of pharmacological targets that, in the future, may curtail the
development of DR.
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